8-K filing — PTC THERAPEUTICS, INC. (PTCT)
Filed: 2026-08-28 AccNo: 0001070081-26-000019 Size: 165 KB Item 1.01: Entry into a Material Definitive Agreement
Stocks · News reference
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PTC Therapeutics To Present New Sephience Data At The 2026 Society For The Study Of Inborn Errors Of Metabolism Annual Symposium, August 25-28
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.